NASDAQ:TVRD Tvardi Therapeutics Q3 2026 Earnings Results & Report $1.12 -0.04 (-3.12%) As of 12:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Tvardi Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.48 versus the -$0.51 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market Opens Tvardi Therapeutics EPS ResultsActual EPS-$0.48Consensus EPS -$0.51Beat/MissBeat by +$0.03One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersTvardi Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Tvardi Therapeutics Q3 2026 Earnings FAQ Did Tvardi Therapeutics beat earnings estimates for Q3 2026? Tvardi Therapeutics (NASDAQ:TVRD) reported earnings of -$0.48 per share for Q3 2026, beating the consensus estimate of -$0.51. The report was announced on Friday, November 13, 2026. Tvardi Therapeutics Earnings HeadlinesTvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business UpdateNovember 13 at 7:00 AM | globenewswire.comChardan Initiates Tvardi Therapeutics at Buy With $8 Price TargetOctober 20, 2026 | marketscreener.comM$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 13 at 1:00 AM | Profits Run (Ad)Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare ConferenceOctober 14, 2026 | markets.businessinsider.comTvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare ConferenceOctober 14, 2026 | globenewswire.comTvardi pubblica dati preclinici su inibitore STAT3 per la coliteSeptember 25, 2026 | it.investing.comSee More Tvardi Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tvardi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tvardi Therapeutics and other key companies, straight to your email. Email Address About Tvardi TherapeuticsTvardi Therapeutics (NASDAQ:TVRD) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development. The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers. The company’s development strategy is centered on targeting disease-driving biological pathways that may support tumor progression and improve responses to existing treatments. Tvardi Therapeutics is headquartered in Houston, Texas, and conducts its research and clinical development activities through collaborations and clinical sites in the United States and other locations as applicable. As a clinical-stage company, its products remain investigational and have not been approved for commercial use.View Tvardi Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
